Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marko Skelin

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Annals of Hematology|April 24, 2022
Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetateIvan Krečak, Sandra Celić-Bunikić, Marko Skelin, et al.
Journal of Chemotherapy (Florence, Italy)|May 13, 2022
The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysisMarko Skelin, David Šarčević, Dina Lešin Gaćina, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|March 30, 2023
Hematocrit to hemoglobin ratio (HHR) may improve prognostication in patients with pulmonary embolismIvan Krečak, Monika Čeko, Karla Nižetić, et al.
Journal of Chemotherapy (Florence, Italy)|April 23, 2025
Immunotherapy in mesothelioma - systematic review and meta-analysis of immunotherapy impact on OS and its correlation with PFS and ORRMarko Skelin, Kaja Matić, Andrea Anić-Matić, et al.
Reviews in Cardiovascular Medicine|January 29, 2022
Comparison of media and academic attention of recently published positive and neutral or negative randomized cardiovascular clinical trialsMarko Skelin, Josip Katić, David Šarčević, et al.
Pharmacology Research & Perspectives|July 7, 2025
Aspirin Versus LMWH for Thromboprophylaxis Following Hip or Knee Arthroplasty-Clinical Implications and Budget ImpactEugen Javor, Andrej Belančić, Patrik Javor, et al.
Heliyon|August 26, 2024
No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot studyIvan Krečak, Josipa Antonija Bačić, Nevena Šimunić, et al.
Pharmacology|January 3, 2024
Prolonged Proton Pump Inhibitor Use and Thrombohemorrhagic Risk in Essential Thrombocythemia and Polycythemia Vera Patients Treated with Long-Term Aspirin: A Pilot StudyIvan Krečak, Ljerka Pivac, Hrvoje Holik, et al.
Oncology Research|April 30, 2024
Levels of evidence and grades of recommendation supporting European society for medical oncology clinical practice guidelinesMarko Skelin, Bruna Perkov-Stipičin, Sanja Vušković, et al.
Acta Diabetologica|April 6, 2026
Differentiating polycythemia vera from sodium-glucose cotransporter 2 inhibitor-associated polycythemiaIvan Krecak, Marija Valovicic Krecak, Tina Marketin, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Annals of Hematology|April 24, 2022
Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetateIvan Krečak, Sandra Celić-Bunikić, Marko Skelin, et al.
Journal of Chemotherapy (Florence, Italy)|May 13, 2022
The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysisMarko Skelin, David Šarčević, Dina Lešin Gaćina, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|March 30, 2023
Hematocrit to hemoglobin ratio (HHR) may improve prognostication in patients with pulmonary embolismIvan Krečak, Monika Čeko, Karla Nižetić, et al.
Journal of Chemotherapy (Florence, Italy)|April 23, 2025
Immunotherapy in mesothelioma - systematic review and meta-analysis of immunotherapy impact on OS and its correlation with PFS and ORRMarko Skelin, Kaja Matić, Andrea Anić-Matić, et al.
Reviews in Cardiovascular Medicine|January 29, 2022
Comparison of media and academic attention of recently published positive and neutral or negative randomized cardiovascular clinical trialsMarko Skelin, Josip Katić, David Šarčević, et al.
Pharmacology Research & Perspectives|July 7, 2025
Aspirin Versus LMWH for Thromboprophylaxis Following Hip or Knee Arthroplasty-Clinical Implications and Budget ImpactEugen Javor, Andrej Belančić, Patrik Javor, et al.
Heliyon|August 26, 2024
No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot studyIvan Krečak, Josipa Antonija Bačić, Nevena Šimunić, et al.
Pharmacology|January 3, 2024
Prolonged Proton Pump Inhibitor Use and Thrombohemorrhagic Risk in Essential Thrombocythemia and Polycythemia Vera Patients Treated with Long-Term Aspirin: A Pilot StudyIvan Krečak, Ljerka Pivac, Hrvoje Holik, et al.
Oncology Research|April 30, 2024
Levels of evidence and grades of recommendation supporting European society for medical oncology clinical practice guidelinesMarko Skelin, Bruna Perkov-Stipičin, Sanja Vušković, et al.
Acta Diabetologica|April 6, 2026
Differentiating polycythemia vera from sodium-glucose cotransporter 2 inhibitor-associated polycythemiaIvan Krecak, Marija Valovicic Krecak, Tina Marketin, et al.
Pageof 7